JP2022531911A5 - - Google Patents

Info

Publication number
JP2022531911A5
JP2022531911A5 JP2021566227A JP2021566227A JP2022531911A5 JP 2022531911 A5 JP2022531911 A5 JP 2022531911A5 JP 2021566227 A JP2021566227 A JP 2021566227A JP 2021566227 A JP2021566227 A JP 2021566227A JP 2022531911 A5 JP2022531911 A5 JP 2022531911A5
Authority
JP
Japan
Application number
JP2021566227A
Other languages
Japanese (ja)
Other versions
JP7741732B2 (ja
JP2022531911A (ja
JPWO2020224606A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/088836 external-priority patent/WO2020224606A1/zh
Publication of JP2022531911A publication Critical patent/JP2022531911A/ja
Publication of JPWO2020224606A5 publication Critical patent/JPWO2020224606A5/ja
Publication of JP2022531911A5 publication Critical patent/JP2022531911A5/ja
Priority to JP2025146817A priority Critical patent/JP2025183279A/ja
Application granted granted Critical
Publication of JP7741732B2 publication Critical patent/JP7741732B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566227A 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用 Active JP7741732B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025146817A JP2025183279A (ja) 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910376652 2019-05-07
CN201910376652.8 2019-05-07
PCT/CN2020/088836 WO2020224606A1 (zh) 2019-05-07 2020-05-06 靶向bcma的工程化免疫细胞及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025146817A Division JP2025183279A (ja) 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用

Publications (4)

Publication Number Publication Date
JP2022531911A JP2022531911A (ja) 2022-07-12
JPWO2020224606A5 JPWO2020224606A5 (https=) 2023-05-19
JP2022531911A5 true JP2022531911A5 (https=) 2023-05-19
JP7741732B2 JP7741732B2 (ja) 2025-09-18

Family

ID=73051240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566227A Active JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用
JP2025146817A Pending JP2025183279A (ja) 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025146817A Pending JP2025183279A (ja) 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用

Country Status (11)

Country Link
US (2) US11840575B2 (https=)
EP (1) EP3967329B1 (https=)
JP (2) JP7741732B2 (https=)
KR (1) KR20220017914A (https=)
CN (2) CN118184800A (https=)
AU (1) AU2020270298A1 (https=)
CA (1) CA3139346A1 (https=)
IL (1) IL287873A (https=)
SG (1) SG11202112382WA (https=)
TW (1) TWI771677B (https=)
WO (1) WO2020224606A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086055B2 (en) * 2016-06-01 2018-10-02 Promab Biotechnologies, Inc. Adherent cancer cell line expressing a hematological tumor antigen
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN113784733B (zh) * 2019-05-07 2024-09-06 亘喜生物科技(上海)有限公司 靶向bcma的工程化免疫细胞及其用途
CA3139346A1 (en) 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
WO2020231882A2 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
JP7629414B2 (ja) * 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたt細胞の組み合わせ
TWI797610B (zh) * 2020-05-06 2023-04-01 大陸商亘喜生物科技(上海)有限公司 人源化cd19抗體及其應用
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
CN112778427B (zh) * 2021-01-29 2022-03-15 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
CN114317607B (zh) * 2021-12-31 2024-08-02 苏州桑尼赛尔生物医药有限公司 融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
CN117143248A (zh) * 2022-05-24 2023-12-01 合源康华医药科技(北京)有限公司 靶向bcma-cd19的双特异性嵌合抗原受体及其应用
EP4532695A1 (en) * 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
CN116023504B (zh) * 2022-06-07 2025-09-30 江苏蒙彼利生物科技有限公司 双特异性嵌合抗原受体(car)及其制备方法
CN116063556B (zh) * 2022-08-18 2023-06-16 再少年(北京)生物科技有限公司 Ips来源的car-nk细胞及其治疗癌症的用途
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用
CN116814553A (zh) * 2023-03-30 2023-09-29 广州百吉生物制药有限公司 杀伤和存续能力增强型car-t细胞及其制备和应用
CN116444669B (zh) * 2023-04-04 2024-02-13 科弈(浙江)药业科技有限公司 靶向bcma car-t细胞人源化抗体
WO2024215708A2 (en) * 2023-04-11 2024-10-17 AbelZeta Inc. Bispecific chimeric antigen receptors targeting bcma and cd19
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
CN117126891A (zh) * 2023-08-30 2023-11-28 广东君厚生物医药有限公司 一种逆转录病毒表达载体及包括其的car-t细胞
CN121320261A (zh) * 2024-07-12 2026-01-13 南京驯鹿生物技术股份有限公司 靶向bcma和gprc5d的双特异性car-t细胞
CN120424217B (zh) * 2025-04-30 2026-03-06 立凌生物制药(苏州)有限公司 靶向b细胞抗原和t细胞抗原的多特异性抗体及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
EP4303232A3 (en) * 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US20160333108A1 (en) * 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
MX383150B (es) 2014-06-02 2025-03-13 Us Health Receptores quiméricos de antígeno que tienen como diana a cd-19.
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
RU2018119706A (ru) 2015-10-30 2019-12-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способ прогноза
CN116063544A (zh) 2016-02-03 2023-05-05 安进研发(慕尼黑)股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
US20170233484A1 (en) * 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US20190336504A1 (en) * 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
MA46236A (fr) 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
JP2019535262A (ja) 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
SG11201903830TA (en) 2016-11-22 2019-05-30 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
AU2017370644A1 (en) 2016-12-05 2019-06-13 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
US20190381171A1 (en) * 2017-02-17 2019-12-19 Unum Therapeutics Inc. Co-use of anti-bcma antibody and antibody-coupled t cell receptor (actr) in cancer therapy and b cell disorders
AU2018269194B2 (en) * 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
CA3287539A1 (en) 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
CN109593721B (zh) * 2017-09-30 2022-11-01 亘喜生物科技(上海)有限公司 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
SG11202011383VA (en) 2018-05-31 2020-12-30 Univ Washington Chimeric antigen receptor t cells (car-t) for the treatment of cancer
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
CA3109959A1 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN109485734B (zh) * 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3139346A1 (en) 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
CN113784733B (zh) * 2019-05-07 2024-09-06 亘喜生物科技(上海)有限公司 靶向bcma的工程化免疫细胞及其用途
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
CN115777017A (zh) * 2020-05-06 2023-03-10 亘喜生物科技(上海)有限公司 用于t细胞工程改造的组合物及方法
AU2024320048A1 (en) * 2023-08-10 2026-03-26 Gracell Biotechnologies (Shanghai) Co., Ltd. Use of dual-target car-t cells in treating b-cell autoimmune diseases

Similar Documents

Publication Publication Date Title
JP2022531911A5 (https=)
JP1673239S (https=)
CN305536290S (https=)
CN306083737S (https=)
CN305537154S (https=)
CN305537038S (https=)
CN305536470S (https=)
CN305536205S (https=)
CN305535311S (https=)
CN305534819S (https=)
CN305534658S (https=)
CN305531865S (https=)
CN305531635S (https=)
CN305531347S (https=)
CN305530642S (https=)
CN306364569S (https=)
CN306363282S (https=)
CN306161631S (https=)
CN306160359S (https=)
CN306088086S (https=)
CN306085621S (https=)
CN306085098S (https=)
CN306070749S (https=)
CN306070340S (https=)
CN306067852S (https=)